SCHEMBL1883147

SCHEMBL1883147

Cc1cc(-c2sc(NC(=O)NCC(=O)N(C)C)nc2C)cc(C)n1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 14/20 0.43
PIK3CG P48736 14/20 0.43
PIK3CA P42336 13/20 0.43
PIK3CB P42338 13/20 0.43
PI4KB Q9UBF8 4/20 0.43
PRMT3 O60678 1/20 0.41
MAPK1 P28482 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CLK2 P49760 2/20 0.40
DYRK3 O43781 1/20 0.40
MAP4K4 O95819 1/20 0.40
DYRK1A Q13627 1/20 0.40
MINK1 Q8N4C8 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
XIAP P98170 1/20 0.39
PIK3R1 P27986 1/20 0.38
CLK1 P49759 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1891019 0.88 PIK3CG (0.51) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL1884085 0.82 GAA (0.38) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL1881199 0.80 PRMT3 (0.36) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL1880326 0.79 PIK3CA (0.42) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL1786368 0.78 PIK3CD (0.68) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL1888741 0.76 PIK3CG (0.65) PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1
SCHEMBL1787019 0.76 PIK3CD (0.70) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL1884090 0.76 ALDH1A1 (0.38) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL1888627 0.74 PIK3CA (0.53) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL1889391 0.74 PIK3CG (0.55) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2157091-B1 Inhibitors of phosphatidylinositol 3-kinase NOVARTIS AG (CH) 2015-06-10 EP disclosed
US-20130172349-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE NOVARTIS AG (CH) 2013-07-04 US disclosed
US-8404684-B2 Inhibitors of phosphatidylinositol 3-kinase NOVARTIS AG (CH) 2013-03-26 US disclosed
US-20110105535-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE NOVARTIS AG 2011-05-05 US disclosed
EP-2157091-A1 Inhibitors of phosphatidylinositol 3-kinase Novartis AG (CH) 2010-02-24 EP disclosed
EP-1622897-B1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE NOVARTIS AG (CH) 2009-10-14 EP disclosed
US-20070032487-A1 Inhibitors of phosphatidylinositol 3-kinase NOVARTIS AG (CH) 2007-02-08 US disclosed
EP-1622897-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE Novartis AG (CH) 2006-02-08 EP disclosed
WO-2004096797-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE NOVARTIS AG (CH) 2004-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032487-A1 Inhibitors of phosphatidylinositol 3-kinase PIK3CA, PIP4K2C, PIP4K2B PIK3CD 4/4885PIK3CG 10/4885PIK3CA 1/4885
US-20110105535-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE PIK3CA, PIK3CD, PIP4K2C PIK3CD 2/4885PIK3CG 8/4885PIK3CA 1/4885
US-20130172349-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE PIK3CA, PIK3CD, PIP4K2C PIK3CD 2/4885PIK3CG 8/4885PIK3CA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.